Co-Diagnostics

Co-Diagnostics Net Tangible Assets

The Net Tangible Assets of Co-Diagnostics (CODX) as of Nov 20, 2026 is 20.63 M USD. In the previous year, Net Tangible Assets was 28.21 M USD — a change of -26.88% (lower).

Net Tangible Assets

20.63 MUSD

YoY

-26.88%

Last updated:

Net Tangible Assets of Co-Diagnostics is 2025 20.63 M USD. Net Tangible Assets of Co-Diagnostics was 2024 28.21 M USD. It decreases by -26.88% lower compared to the previous year.

The Co-Diagnostics Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
-1.06 M USD
Jan 1, 2019
1.74 M USD
Jan 1, 2020
66.70 M USD
Jan 1, 2021
92.57 M USD
Jan 1, 2022
87.72 M USD
Jan 1, 2023
59.61 M USD
Jan 1, 2024
28.21 M USD
Jan 1, 2025
20.63 M USD
The Co-Diagnostics Net Tangible Assets history
YEARNet Tangible AssetsYoY
20.63 MUSD-26.88%
28.21 MUSD-52.67%
59.61 MUSD-32.05%
87.72 MUSD-5.24%
92.57 MUSD+38.79%
66.70 MUSD+3,739.19%
1.74 MUSD-264.08%
-1.06 MUSD-127.50%
3.85 MUSD-228.58%
-2.99 MUSD+160.99%
-1.15 MUSD-927.67%
138,628.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Net Tangible Assets of Co-Diagnostics is 20.63 M USD in 2025.

Net Tangible Assets of Co-Diagnostics changed from 28.21 M USD to 20.63 M USD, representing a -26.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Co-Diagnostics

All Key Metrics — Co-Diagnostics